RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with high-risk NSMP endometrial cancer. Patients will be randomised to radiotherapy with chemotherapy (standard of care), or radiotherapy followed by oral progestin tablets.

Start Date29 Jun 2026

Sponsor / Collaborator

University College London

NCT07570433

/ Not yet recruitingPhase 4IIT

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial (HORUS-COPE): An International Proof-of-concept Clinical Trial on Modulation of Immunosuppressive Regimen in Solid-organ Transplant Recipients With Cytomegalovirus Infection.

Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality following organ transplantation.
Cell-mediated immunity plays a crucial role in controlling CMV replication after transplantation. Immune monitoring involves the use of immune biomarkers to dynamically estimate the risk of CMV replication. This approach allows for the individualization of preventive and therapeutic strategies, improving patient outcomes.
The HORUS-COPE trial is designed to assess the effect of immune modulation on CMV replication kinetics and to explore the performance of a selected immune signature during antiviral therapy for CMV infection to stratify patients based on their risk of not responding to immune modulation.

Start Date01 Apr 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire Vaudois

NCT07319429

/ RecruitingPhase 2/3IIT

Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification: a Prospective Multicenter Umbrella Clinical Study（FEMUS）

Endometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC patients. High-potency progestogens remain the sole therapeutic option recommended by international guidelines for this patient population; however, approximately 30% of patients exhibit no response to such treatment.
The concept of EC molecular subtyping, proposed by The Cancer Genome Atlas (TCGA) in 2013, has revolutionized the diagnosis and management of EC. EC subtypes with distinct molecular features demonstrate substantial differences in biological behaviors and responses to pharmacotherapeutic interventions. Nevertheless, the role of molecular subtyping in guiding FST decision-making-both in terms of its applicability and specific mechanisms-remains an unmet research need worldwide.
Notably, the POLE-mutant and microsatellite instability-high (MSI-H) subtypes display the highest sensitivity to immune checkpoint inhibitors, underscoring the clinical value of exploring their utility in FST. The no specific molecular profile (NSMP) subtype is sensitive to progestogens but lacks reliable predictive biomarkers-accurate pre-treatment prediction would enable tailored treatment selection, shorten treatment duration, and enhance therapeutic outcomes. In contrast, the p53-abnormal (p53abn) subtype is associated with a poor prognosis, and FST is therefore not recommended for this subgroup.
Building on the aforementioned background and our research team's preliminary clinical findings, this project focuses on the field of FST for EC. To address the current challenges-including narrow indications, limited treatment options, suboptimal efficacy, and the absence of precise personalized regimens-we aim to conduct the world's first prospective multicenter umbrella trial based on EC molecular subtyping. Optimal novel diagnostic and therapeutic protocols will be developed for each molecular subtype, with the goals of optimizing existing FST strategies, improving FST efficacy and reproductive outcomes, expanding eligible indications, and providing high-quality clinical evidence for molecular subtype-guided FST in EC, thereby advancing the overall effectiveness of FST for EC patients.

Start Date25 Jan 2026

Sponsor / Collaborator

Fudan University

100 Clinical Results associated with Medroxyprogesterone Acetate

100 Translational Medicine associated with Medroxyprogesterone Acetate

100 Patents (Medical) associated with Medroxyprogesterone Acetate

6,550

Literatures (Medical) associated with Medroxyprogesterone Acetate

31 Dec 2026·Human Fertility

Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol

Article

Author: Sherlock, K. ; Kastora, S. ; Alabi, C. ; Vaughan, E. ; Yasmin, E. ; Lavery, S. ; Balachandren, N. ; Atik, Y. ; Davies, M. C.

Suppression of an LH surge is fundamental to successful oocyte retrieval after controlled ovarian stimulation. This study evaluates the efficacy and cost-effectiveness of progestin-primed ovarian stimulation (PPOS) using oral medroxyprogesterone acetate in fertility preservation cycles. The design is a retrospective single-centre study (January 2022-August 2023) comparing two ovarian stimulation protocols: PPOS and the gonadotrophin-releasing hormone antagonist (GnRHant) protocols. Cycles began at any time of the menstrual cycle. The primary outcome was the number of metaphase II oocytes retrieved. Secondary outcomes included total oocytes retrieved, maturity ratio, stimulation duration, incidence of premature LH rise/ovulation events, and the cost of medication used to prevent ovulation. The study included 125 fertility preservation cycles: 54 in the PPOS group and 71 in the GnRHant group. Median body mass index, antral follicle count, and anti-Mullerian hormone levels were comparable between the two groups. The median age was younger in the PPOS group; 28 years vs. 32 years, p = 0.03. Mature oocyte retrieval was similar; mean 9.33 [SD 5.87] vs. 8.97 [SD 5.44], p = 0.73. No premature LH rises occurred in either group. Secondary outcomes showed no significant differences, except for the cost of medication used to prevent ovulation. The PPOS protocol was considerably more cost-effective, by achieving a 98.06% cost reduction (medroxyprogesterone acetate, mean £4.38 [SD, £1.10] vs cetrorelix acetate £226.2 [SD £64.36], p= <0.0001. PPOS is a practical, cost-effective strategy for fertility preservation. Its appeal lies in its patient-centric focus, with a less invasive injection-based administration, while maintaining comparable effectiveness and significant cost reduction compared with the GnRH antagonist ovarian stimulation protocol.

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

Metformin sensitizes endometriosis to medroxyprogesterone acetate treatment through MIG-6 mediated signaling

Article

Author: Gao, Guanwen ; Zhao, Huashan ; Liu, Degao ; Li, Changzhong ; Dai, Wenkui ; Zhu, Fanyue ; Wang, Yunfei ; Lin, Jinju ; Geng, Lina ; Duan, Lvfang

This study evaluates the synergistic therapeutic effect of metformin (MET) combined with medroxyprogesterone acetate (MPA) on endometriosis (EM) and investigates the involvement of the steroid receptor coactivator-1 (SRC-1) and mitogen-inducible gene 6 (MIG-6). Immunohistochemical analysis revealed significantly decreased SRC-1, progesterone receptor (PGR), and MIG-6 protein expression in human ectopic EM lesions compared to normal eutopic endometrium. In an EM mouse model, the combination of metformin (MET) and MPA resulted in the greatest reduction of ectopic lesion size and weight compared to either treatment alone. This combination therapy also uniquely increased serum Eotaxin and decreased interleukin-12p40 levels. Transcriptome analysis demonstrated specific enrichment of immune activation pathways only in the combination treatment group. In vitro, using the human endometriosis epithelial cell line 12Z, the MET and MPA combination significantly suppressed cell proliferation and migration, concomitant with an upregulation of SRC-1, PGR, and MIG-6 messenger RNA expression. We conclude that MET enhances the therapeutic efficacy of MPA against EM. This effect may be mediated through MIG-6 signaling and involves the upregulation of SRC-1, inhibiting ectopic cell proliferation and migration, and inhibiting endometriotic lesion progression, representing a novel strategy to overcome progesterone resistance. KEY MESSAGES: SRC-1, MIG-6, and PGR are downregulated in human endometriotic lesions. MET and MPA act cooperatively to suppress lesion growth in a murine model. Combination therapy increases Eotaxin levels while decreasing IL-12p40 in mice. MET and MPA activate immune surveillance pathways within lesions. MET and MPA synergistically inhibit endometriotic cell growth and migration.

01 Dec 2026·CONTRACEPTION

Postpartum contraception plans among a cohort of pregnant incarcerated individuals

Article

Author: Sufrin, Carolyn ; Jackson, Jamie ; Upputuri, Sreya ; Knittel, Andrea K ; Falk, Isabelle ; Arora, Kavita Shah ; Boynton, Marcella ; Carmody, Mary D ; Larkin, Suzanna

OBJECTIVE:

Our objective was to describe patterns of postpartum contraception plan documentation and fulfillment among patients receiving prenatal care in a state prison system.

STUDY DESIGN:

This is a retrospective chart review of patients over age 21 who accessed prenatal care in a state prison clinic between January 1, 2016 and December 31, 2021. We described demographic characteristics, contraception plans documented during prenatal care, and fulfillment of contraception method by hospital discharge for patients who delivered while incarcerated. For patients who had prenatal care for two or more trimesters, we also assessed the consistency of documented contraception plans.

RESULTS:

Of the total 890 patients, only 44.2% of all patients had documentation of a postpartum contraception plan while incarcerated. Overall, long-acting reversible contraception (9.1%) and permanent contraception (8.9%) were the most commonly documented plans. Of the 74 patients with a contraceptive plan documented in two or three trimesters, 64.9% consistently had one plan documented at all visits. Over half, 472 (53.0%), delivered while incarcerated and the most common type of contraception method provided at delivery was depot medroxyprogesterone acetate (13.1%) despite only 2.8% of patients having documentation of this method as their contraception plan during prenatal care visits while incarcerated.

CONCLUSIONS:

Less than half of the patients in the study sample had documentation of their desired goal for postpartum contraception. Patterns of documentation and fulfillment were likely a byproduct of a combination of individual preferences, anticipated length of incarceration, clinician practice patterns, and facility policies.

IMPLICATIONS:

There may be misalignment between patient preferences for postpartum contraception method and what is discussed, documented, or provided during incarceration.

News (Medical) associated with Medroxyprogesterone Acetate

18 Aug 2026

·www.prnewswire.com

Legal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation

Mass-tort funding company estimates approximately 5,000 claims could resolve for an aggregate value exceeding $1.2 billion; settlement terms remain confidential. ORLANDO, Fla., Aug. 18, 2026 /PRNewswire/ -- Legal Bay LLC, a pre-settlement funding company with extensive experience in mass-tort litigation, announced today that Pfizer Inc. and plaintiffs' leadership have entered into a settlement program intended to resolve a substantial percentage of the federal lawsuits alleging that Depo-Provera caused intracranial meningiomas. The settlement represents a potentially significant development in the rapidly evolving Depo-Provera litigation. In an August 10, 2026, case-management order, the U.S. District Court for the Northern District of Florida stated that the parties had entered into a settlement memorialized in an agreement dated July 22, 2026. The court reported that 6,289 cases were then pending in the multidistrict litigation. Financial terms of the agreement are confidential, and neither the court nor the settling parties has publicly confirmed an aggregate settlement value range or average individual award. Based on information and Legal Bay's assessment of comparable mass-tort resolutions, the company estimates that approximately 5,000 claims may ultimately resolve for more than $1.2 billion - an estimated average of roughly $250,000 per participating claimant. Actual compensation, if any, will depend on the settlement program's eligibility requirements, medical documentation, product-use history, injury severity and other individual factors. Legal Bay believes that certain qualifying claims involving severe injuries could potentially receive substantially higher awards, possibly approaching $1 million. These estimates are not guaranteed and have not been confirmed by Pfizer, plaintiffs' leadership or the settlement administrator. Pfizer has not admitted fault or liability in connection with the settlement. The company has previously defended Depo-Provera's safety and efficacy profile and contested allegations that it failed to provide adequate warnings. Chris Janish, CEO of Legal Bay, says, "Legal Bay has followed and supported this litigation for a considerable time, including through our involvement at conferences nationwide. While we recognize Pfizer as a major global pharmaceutical company, plaintiffs' attorneys have presented scientific evidence concerning the alleged association between Depo-Provera and intracranial meningiomas that demanded serious attention. This settlement program is an important development for claimants who have faced medical, emotional and financial uncertainty." Settlement implementation in complex mass-tort litigation can take considerable time and payment could take years for some cases. However, plaintiffs with confirmed brain tumor cases are pre-approved with Legal Bay for lowest pre-settlement funding rates industry wide. And funding can happen in 24 hours or less in most cases. If you're a lawyer or plaintiff involved in an active lawsuit and need an immediate cash advance against an impending settlement, please visit Legal Bay HERE or call toll-free at 877.571.0405. Participation in settlement is not automatic. Claimants must satisfy the program's requirements, and individual awards and payment schedules have not been publicly disclosed. The court identified November 30, 2026, as the registration deadline for eligible claimants participating in the settlement program. Women who used Depo-Provera and were diagnosed with an intracranial meningioma and don't have a Depo-Provera lawyer yet can reach out to Legal Bay so they can put you in touch with one of the best Depo Provera law firms in country, as time to file a claim is closing with this settlement news. You need to be represented by an attorney to receive a lawsuit cash advance. Legal Bay does not provide legal advice, and prior results or settlement estimates do not guarantee a particular outcome. Legal Bay is known as one of the best lawsuit loan companies in the industry, offering competitive rates and quick turnaround, often within 24–48 hours once documentation is received. They offer pre-settlement funding, lawsuit loans, loans for lawsuits, and cash settlement funding to plaintiffs involved in a wide range of cases, including slip and fall accidents, car and truck accidents, construction accidents, personal injury, and more. These pre settlement loans are non-recourse, meaning clients only repay the advance if they win their case. If not, there is no obligation to repay. To apply right now for a loan settlement program, please visit the company's website HERE or call toll-free at 877.571.0405, where agents are standing by to answer any questions. Source: Legal Bay, LLC Contact: Chris Janish, CEO Email: info@Legal Bay.com Ph.: 877.571.0405 Website: Bay.com Follow Us on Social Media: Facebook Instagram LinkedIn SOURCE Legal-Bay LLC 21% more press release views with Request a Demo

Patent Infringement

30 Jul 2026

·www.einpresswire.com

Vigna Law Group: Bellwether Early Use of Depo-Provera in Focus, 1992-2002

We represent dozens of women with early use, who, like our California clients we represent in the coming trials, were prescribed Depo-Provera between 1992 and 2002.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, July 30, 2026 / EINPresswire.com / -- “We represent four Defense Bellwether selections in the California consolidated litigation involving women who were prescribed Depo-Provera before 2002. These cases involve allegations concerning Pfizer's conduct from the 1950s through the 1990s that are part of the ongoing litigation," states Greg Vigna, MD, JD, national neurological injury attorney. Dr. Greg Vigna, MD, JD, states, "We represent dozens of women who were prescribed Depo-Provera between 1992 and 2002, including clients involved in the upcoming California bellwether trials. The company requires signal analysis for newly described complaints. The litigation includes allegations regarding whether Depo-Provera is associated with a dose-dependent increase in meningiomas and how reports and safety signals were evaluated over time." Dr. Vigna adds, “As part of our representation, we are reviewing issues related to signal analysis. Through the California JCCP discovery process, we have requested emails and other documents relating to meningioma reports submitted to Pfizer. The litigation includes allegations regarding whether the company's conduct was consistent with applicable regulatory and good clinical practice requirements." California Bellwether selections represented by the Vigna Law Group: California: Case No. 26CV189984, Case No. 26CV179081, Case No. 26CV178116, Case No. 26CV179212 Click here to read about signal analysis, “Practical applications of regulatory requirements for signal detection and communications in pharmacovigilance” published in Therapeutic Advance in Drug Safety, 2020, Vol. 11: 1-15. Discover crucial insights by watching Dr. Vigna’s educational episode on Justice with Dr. V. He is an expert in brain injuries and a personal injury and pharmaceutical injury attorney. This seven-minute explainer delves into the symptoms associated with Depo-Provera and meningiomas, providing essential information to guide your health decisions: Meningiomas Explained: Growth, Surgery Risks, and What Patients Should Know Watch Justice with Dr.V on TikTok to learn more about Depo-Provera. Dr. Vigna is a California and Washington, D.C., attorney who is active in the Depo-Provera litigation and has cases filed in Minnesota, Connecticut, California, New Hampshire, Wisconsin, Washington, and in the Multidistrict Litigation with the Ben Martin Law Group. To learn more, visit https://vignalawgroup.com/practice-area/meningioma-resection/ California Offices: 8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045 2570 N. First Street, 2nd Floor, San Jose, CA 95131 931 10th Street, #962, Modesto, CA 95354 2281 Lava Ridge Court, Suite 200, Roseville, CA 95661 600 West Broadway, Suite 700, San Diego, CA 92101 Connecticut Office: 515 Centerpoint Drive, Suite #2212, Middletown, CT 06457 Greg Vigna, MD, JD Vigna Law Group +1 817-809-9023 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Patent InfringementClinical Study

24 Jul 2026

·www.einpresswire.com

Latency: Depo-Provera and Meningioma in Focus; California Bellwethers on the Horizon

Attorney Dr. Greg Vigna cites JAMA research alleging Depo-Provera raises meningioma risk Meningiomas have been known to be a biologically plausible complication of progestins, and Pfizer has not studied the drug in a reasonable fashion to understand this risk.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, July 24, 2026 / EINPresswire.com / -- “Meningiomas have been identified as a biologically plausible potential complication associated with progestins, and Pfizer has not conducted what I believe to be sufficient research to fully evaluate this risk,” states Greg Vigna, MD, JD, Bellwether Depo-Provera Attorney. Dr. Greg Vigna, MD, JD, states, "Pfizer has not published an epidemiologic study on Depo-Provera despite the biological plausibility and the safety signals that have been reported in the literature for decades. It has been known since the 1920s that meningiomas may grow during pregnancy and that the meningeal cells express progestin receptors. These findings have contributed to research examining whether exposure to progestins, including Depo-Provera, may be associated with meningioma development and growth." Dr. Vigna states, “Recent data published in JAMA reported an association between Depo-Provera use and an increased risk of meningioma. The study also reported a lower Number Needed to Harm (NNH) for Depo-Provera than for other progestins evaluated. The latency between exposure and diagnosis may also be an important consideration when interpreting these findings.” Click here to read Contraceptive Progestogens and Incident Meningioma, published in JAMA Network Open. Dr. Vigna adds, “My firm, along with my co-counsels, has five of the eight bellwether cases in the California JCCP and has filed state court cases in Minnesota, Connecticut, Washington, Wisconsin, and New Hampshire. The number of state court cases continues to grow as women who allege they developed meningiomas following Depo-Provera use seek legal representation." Case No. 26CV189984 Case No. 26CV179081 Case No. 26CV178116 Case No. 26CV179212 Case No. 25CV156918 Dr. Vigna concludes, "Our firm continues to pursue litigation involving allegations that Depo-Provera was not adequately studied with respect to meningioma risk before its approval in 1992 and that additional safety evaluation was warranted." Discover crucial insights by watching Dr. Vigna’s educational episode on Justice with Dr. V. This two-minute explainer delves into the symptoms associated with Depo-Provera and meningiomas, providing essential information to guide your health decisions: Depo-Provera and Meningioma Risk: What the FDA Warning Means Watch Justice with Dr. V on TikTok to learn more about Depo-Provera. Dr. Vigna is a California and Washington D.C., lawyer and is Co-Counsel with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent women who have suffered meningiomas. Learn more: https://vignalawgroup.com/practice-area/meningioma-resection/ California Offices: 8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045 2570 N. First Street,2nd Floor, San Jose, CA 95131 931 10th Street, #962, Modesto, CA 95354 2281 Lava Ridge Court, Suite 200, Roseville, CA 95661 600 West Broadway, Suite 700, San Diego, CA 92101 Connecticut Office: 515 Centerpoint Drive, Suite #2212, Middletown, CT 06457 Greg Vigna, MD, JD Vigna Law Group +1 817-809-9023 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Patent Infringement

100 Deals associated with Medroxyprogesterone Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D00951	Medroxyprogesterone Acetate	L02AB02 G03AC06 G03DA02	DB00603

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Suppression of ovulation	Japan	Kyowa Kirin Co., Ltd.	11 Mar 2022
Pain	United States	Pfizer Inc.	04 Dec 2020
Contraception	United States	Pfizer Inc.	17 Dec 2004
Pregnancy	United States	Pfizer Inc.	29 Oct 1992
Breast Cancer	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Endometrial Carcinoma	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Prostatic Cancer	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Renal Cell Carcinoma	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Abortion, Habitual	Japan	Pfizer Japan, Inc.	25 Jan 1963
Abortion, Threatened	Japan	Pfizer Japan, Inc.	25 Jan 1963
Hypomenorrhea	Japan	Pfizer Japan, Inc.	25 Jan 1963
Infertility	Japan	Pfizer Japan, Inc.	25 Jan 1963
Menorrhagia	Japan	Pfizer Japan, Inc.	25 Jan 1963
Menstruation Disturbances	Japan	Pfizer Japan, Inc.	25 Jan 1963
Amenorrhea	United States	Pfizer Inc.	18 Jun 1959
Endometrial Hyperplasia	United States	Pfizer Inc.	18 Jun 1959
Metrorrhagia	United States	Pfizer Inc.	18 Jun 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Atopic	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Eczema	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Neurodermatitis	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Osteoporosis, Postmenopausal	Phase 1	-	Wyeth AB	01 Sep 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESGO2026	Not Applicable	Endometrial Carcinoma	67	Combined oral progesterone (medroxyprogesterone 500mg) and levonorgestrel-releasing intrauterine system (LNG-IUS)	lazfegbwtr(oayorxwavo) = bdpxypezzf etcnxqfdtz (nilrwuagjd ) View more	Positive	28 Feb 2026
NCT05726903 (CTgov)	Phase 4	-	35	Depo-subQ Provera	tqjvpstqxg(teuobwwyjj) = tszvknfesj aoshqrvtfe (eezwnyiljn, hrbsgjymez - ycxhrmvbaw) View more	-	12 Feb 2026
NCT04669678 (EPIC, CTgov)	Phase 4	Medication interactions \| HIV Infections \| Contraception	110	Etonogestrel (Group 1 DOR + ETG)	ixmjezitew(tdeblhsybd) = sxvkkerzsr aexlbupmsr (jzvzwvzcvy, hwtcrveidi - ophihjcahh) View more	-	08 Apr 2025
				Intramuscular depo-medroxyprogesterone acetate (IM DMPA) (Group 2 DOR + IM DMPA)	ixmjezitew(tdeblhsybd) = nclwlvbmdo aexlbupmsr (jzvzwvzcvy, asxcqqmvlf - arpwxobiju) View more
NCT03844633 (Pubmed \| Contraception)	Phase 4	Contraception	150	DMPA	pwuieeirqe(pqaqugtxgt) = nfcbebsnqk bbbiqyuzuz (lwcpuonmqz, 29.4)	Positive	01 Feb 2025
				Placebo or no injection	pwuieeirqe(pqaqugtxgt) = rbzprugeva bbbiqyuzuz (lwcpuonmqz, 36.1)
NCMP-03 (SNO2024)	Not Applicable	Meningioma ER/PR	64	EstrogenroneProgesteroneon (Estrogen or Progesterone use)	ynbhdvfrza(ffdtszlckk) = heuhzcdvig uiqdmpuvlx (mzqnsjkcqx )	Positive	11 Nov 2024
				ProgesteroProgesteronetion (Unopposed Progesterone only use)	ynbhdvfrza(ffdtszlckk) = pdgacpuelw uiqdmpuvlx (mzqnsjkcqx )
ASTRO2024	Not Applicable	Meningioma	-	Progesterone use	jtzietrbtd(eybzxmyqhn) = higxtcbggu bjpxhpllko (fyqhqkkwvz )	-	01 Oct 2024
				Estrogenroneprogesteroneon (Estrogen or progesterone use)	jtzietrbtd(eybzxmyqhn) = eqhxgbbeoq bjpxhpllko (fyqhqkkwvz )
NCT02550067 (ECHO, Pubmed \| BMC Womens Health) Manual	Not Applicable	Contraception	398	Depot medroxyprogesterone acetate (DMPA-IM)	afjxmnzpft(wchdzgznfp) = itgjyhhzuf rauigzbwrg (dikvgrgwfc ) View more	Positive	08 Mar 2024
				copper intrauterine device	afjxmnzpft(wchdzgznfp) = yyqxjwkthd rauigzbwrg (dikvgrgwfc ) View more
FRI413 (ENDO2023)	Not Applicable	occlusions	84	Norethisterone	ytnkzhpqdd(okzktcifjw) = howhwwdjnm ruqqlgyfpt (qyaoukklzf, 0 - 252)	-	05 Oct 2023
NCT05438277 (CTgov)	Phase 4	Shoulder Pain	421	MPA+Methylprednisolone (Methylprednisolone Acetate (MPA))	kglijckkzd = jvbjcxtrqf ybwibgxsvt (osywbesznw, jleqwtrugd - fzfujbcasb) View more	-	07 Mar 2023
				Triamcinolone Acetonide (TA) (Triamcinolone Acetonide (TA))	kglijckkzd = zxgheutmro ybwibgxsvt (osywbesznw, bimdmvmijc - pfpucvpino) View more
NCT02550067 (Pubmed \| Clin Infect Dis)	Not Applicable	Herpes Simplex	4,062	Depot medroxyprogesterone acetate (DMPA-IM)	ongzauunnt(ttkvxoiorz) = zhdrpulmim retwrbfqda (bmtfybwrdj )	-	10 Sep 2022
				Levonorgestrel (LNG) implant	ongzauunnt(ttkvxoiorz) = dtiomwgjpl retwrbfqda (bmtfybwrdj )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis